FDA Approves KEYTRUDA for Head & Neck Cancer as Neoadjuvant and Adjuvant Therapy

The FDA has approved Merck's KEYTRUDA (pembrolizumab) for perioperative treatment of resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, based on trial data showing a 30% reduction in event-free survival events, potentially shifting treatment standards for this cancer type.